The progress on the In Vivo-In Vitro correlation (IVIVC) for immediate release dosage form as an alternative to bioavailability studies

Current Pharmaceutical Analysis

Volumn 6, Issue 4, 2010, Pages 289-298

  Ostrowski, Michat ^a   Ba̧czek, Tomasz ^b  

^a Polfa Warszawa SA   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Bioavailability; Biopharmaceutical classification system (BCS) studies; Immediate release (IR) dosage forms; In vivo in vitro correlation (IVIVC); Review

Indexed keywords

AMOXICILLIN; ANXIOLYTIC AGENT; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; DANAZOL; DERAMICICLANE FUMARATE; FLUTAMIDE; GEMFIBROZIL; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; KETOCONAZOLE; LEVOTHYROXINE; MONTELUKAST; NNC 025 0926; RZ 50; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; BIOEQUIVALENCE; CLINICAL ASSESSMENT TOOL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DYSLIPIDEMIA; HUMAN; IMMEDIATE DRUG RELEASE PREPARATION; IN VIVO IN VITRO CORRELATION; NONHUMAN; PRIORITY JOURNAL; RELIABILITY;

EID: 79952775171     PISSN: 15734129     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341210793292400     Document Type: Article

References (43)

1. Levy, G.; Leonards, J.R.; Procknal, J.A. Development of in vitro dissolution tests which correlate quantitatively with dissolution rate-limited drug absorption in man. J. Pharm. Sci., 1965, 54(12), 1719-1722.
2. Amidon, G.L.; Lennernäs, H.; Shah, V.P.; Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 1995, 12(3), 413-420.
3. FDA Guidance for Industry, Extended release oral dosage forms: Development, Evaluation and Applications of in vitro/in vivo correlations, 1997.
4. El-Yazigi, A.; Sawchuk, R.J. In vitro-in vivo correlation and dissolution studies with oral theophylline dosage forms. J. Pharm. Sci., 1985, 74(2), 161-164.
5. Ostrowski, M.; Wilkowska, E.; Ba-czek, T. In vivo-in vitro correlation for amoxicillin trihydrate 1000 mg dispersible tablet. Drug Dev. Ind. Pharm., 2009, 35, 981-985.
6. Ishii, K.; Katayama, Y.; Itai, S.; Ito, Y.; Hayashi, H. In vitro dissolution tests corresponding to the in vivo dissolution of clarithromycin tablets in the stomach and intestine. Chem. Pharm. Bull. (Tokyo), 1995, 43(11), 1943-1948.
7. Gaynor, C; Dunne, A.; Davis, J. The effects of averaging on accuracy of IVIVC model predictions. J. Pharm. Sci., 2009, 98(10), 3829-3838.
8. Wei, H.; Löbenberg, R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur. J. Pharm. Sci., 2006, 29(1), 45-52.
9. Okumu, A.; DiMaso, M.; Löbenberg, R. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharm. Res., 2008, 25(12), 2778-2785.
10. Lue, B.M.; Nielsen, F.S.; Magnussen, T.; Schou, H.M.; Kristensen, K.; Jacobsen, L.O.; Müllertz, A. Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorlysoluble model compound. Eur. J. Pharm. Biopharm., 2008, 69(2), 648-657.
11. Volpato, N.M.; Silva, R.L.; Brito, A.P.; Gonçalves, J.C.; Vaisman, M.; Noël, F. Multiple level C in vitro/in vivo correlation of dissolution profiles of two L-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism. Eur. J. Pharm. Sci., 2004, 21(5), 655-660.
12. Sunesen, V.H.; Pedersen, B.L.; Kristensen, H.G.; Müllertz, A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur. J. Pharm. Sci., 2005, 24(4), 305-313.
13. Jantratid, E.; Janssen, N.; Chokshi, H.; Tang, K.; Dressman, J.B. Designing biorelevant dissolution tests for lipid formulations: case example-lipid suspension of RZ-50. Eur. J. Pharm. Biopharm., 2008, 69(2), 776-785.
14. Donato, E.M.; Martins, L.A.; Fröehlich, P.E.; Bergold, A.M. Development and validation of dissolution test for lopinavir, a poorly water-soluble drug, in soft gelcapsules, based on in vivo data. J. Pharm. Biomed. Anal, 2008, 47(3), 547-552.
15. Souliman, S.; Blanquet, S.; Beyssac, E.; Cardot, J.M. A level A in vitro/in vivo correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage form. Eur. J. Pharm. Sci., 2006, 27(1), 72-79.
16. Radovanovic, J.; Duric, Z.; Jovanovic, M.; Ibric, S.; Petrovic, M. An attempt to establish an in vitro-in vivo correlation: case of paracetamol immediate-release tablets. Eur. J. Drug Metab. Phar-macokinet., 1998, 23(1), 33-40.
17. Domínguez, A.; Medina, R.; Hurtado, M. Bioequivalence study of paracetamol tablets: in vitro-in vivo correlation. Drug Dev. Ind. Pharm., 2000, 26(8), 821-828.
18. Rostami-Hodjegan, A.; Shiran, M.R.; Tucker, G.T.; Conway, B.R.; Irwin, W.J.; Shaw, L.R.; Grattan, T.J. A new rapidly absorbed paracetamol tablet containing sodiumbicarbonate. II. Dissolution studies and in vitro/in vivo correlation. Drug Dev. Ind. Pharm., 2002, 28(5), 533-543.
19. Parojcic, J.; Vasiljevic, D.; Ibric, S.; Djuric, Z. Tablet disintegration and drugdissolution in viscous media: paracetamol IR tablets. Int. J. Pharm., 2008, 355(1-2), 93-99.
20. Rouini, M.R.; Ardakani, Y.H.; Mirfazaelian, A.; Hakemi, L.; Balu-chestani, M. Investigation on different levels of in vitro-in vivo correlation: gemfibrozil immediate release capsule. Biopharm. Drug Dispos., 2008, 29(6), 349-355.
21. Meyer, M.C.; Straughn, A.B.; Mhatre, R.M.; Shah, V.P.; Williams, R.L.; Lesko, L.J. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm. Res., 1998, 15(11), 1787-1791.
22. Lake, O.A.; Olling, M.; Barends, D.M. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. Eur. J. Pharm. Biopharm., 1999, 48(1), 13-19.
23. Veng-Pedersen, P.; Gobburu, J.V.; Meyer, M.C.; Straughn, A.B. Carbamazepine level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach. Biopharm. Drug Dispos., 2000, 21(1), 1-6.
24. Barzegar-Jalali, M.; Nayebi, A.M.; Valizadeh, H.; Hanaee, J.; Barzegar-Jalali, A.; Adibkia, K.; Anoush, M.; Sistanizad M. Evaluation of in vitro-in vivo correlation and anticonvulsive effect of carbamazepine after cogrinding with microcrystalline cellulose. J. Pharm. Pharm. Sci., 2006, 9(3), 307-316.
25. Kovacevic, I.; Parojcic, J.; Homsek, I.; Tubic-Grozdanis, M.; Langguth, P. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol. Pharm., 2009, 6(1), 40-47.
26. Balan, G.; Timmins, P.; Greene, D.S.; Marathe P.H. In-vitro in-vivo correlation models for glibenclamide after administration of met-formin/glibenclamide tablets to healthy human volunteers. J. Pharm. Pharmacol, 2000, 52(7), 831-838.
27. Posti, J.; Katila, K.; Kostiainen, T. Dissolution rate limited bioavailability of flutamide, and in vitro-in vivo correlation. Eur. J. Pharm. Biopharm., 2000, 49(1), 35-39.
28. Viçosa, A.L.; Chatah, E.N.; Santos, T.C.; Jones, L.F. Jr.; Dantas, C.B.; Dornelas, C.B.; Rodrigues, C.R.; Castro, H.C.; Sousa, V.P.; Dias, L.R.; Cabral, L.M. Bioequivalence studies and sugar-based excipients effects on the properties of new generic ketoconazole tablets formulations and stability evaluation by using direct compression method. Pharm. Dev. Technol, 2009, 14(5), 530-539.
29. Al-Behaisi, S.; Antal, I.; Morovján, G.; Szúnyog, J.; Drabant, S.; Marton, S.; Klebovich, I. In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers. Eur. J. Pharm. Sci., 2002, 15(2), 157-162.
30. Jantratid, E.; Prakongpan, S.; Amidon, G.L.; Dressman, J.B. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clin. Pharmacokinet, 2006, 45(4), 385-399.
31. Alkhalidi, B.A.; Al-Ghazawi, M.; Alkhatib, H.S.; Sallam, A. Development of a predictive in vitro dissolution for clarithromycin granular suspension based on in vitro-in vivo correlations. Pharm. Dev. Technol, 2009, Aug 19. [Epub ahead of print].
32. Shah, V.P.; Prasad, V.K.; Alston, T.; Cabana, B.E.; Gural, R.P.; Meyer, M.C. Phenytoin I: in vitro-in vivo correlation for 100-mg phenytoin sodium capsules. J. Pharm. Sci., 1983, 72(3), 306-308.
33. Mendes, R.W.; Masih, S.Z.; Kanumuri, R.R. Effect of formulation and process variables on bioequivalency of nitrofurantoin II: in vivo-in vitro correlation. J. Pharm. Sci., 1978, 67(11), 1616-1619.
34. Llabrés, M.; Vila, J.L.; Martínez-Pacheco, R. Quantification of the effect of excipients on bioavailability by means of response surfaces III: In vivo-in vitro correlations. J. Pharm. Sci., 1982, 71(8), 930-932.
35. Gordon, M.S.; Chowhan, Z. In vivo/in vitro correlations for four differently dissolving ketorolac tablets. Biopharm. Drug. Dispos., 1996, 17(6), 481-492.
36. Jung, H.; Gonzalez, H.; Rodriguez, J.M. Bioequivalence study of nalidixic acidtablets: in vitro-in vivo correlation. Biopharm. Drug Dispos., 1993, 14(5), 381-388.
37. Schamp, K.; Schreder, S.A.; Dressman, J. Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance. Eur. J. Pharm. Biopharm., 2006, 62(3), 227-234.
38. Jinno, J.; Kamada, N.; Miyake, M.; Yamada, K.; Mukai, T.; Odomi, M.; Toguchi, H.; Liversidge, G.G.; Higaki, K.; Kimura T. In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J. Control Release, 2008, 130(1), 29-37.
39. Khan, M.Z.; Rausl, D.; Zanoski, R.; Zidar, S.; Mikulcic, J.H.; Krizmanic, L.; Eskinja, M.; Mildner, B.; Knezevic, Z. Classification of loratadine based on the biopharmaceutics drug classification concept and possible in vitro-in vivo correlation. Biol Pharm. Bull, 2004, 27(10), 1630-1635.
40. Rossi, R.C.; Dias, C.L.; Donato, E.M.; Martins, L.A.; Bergold, A.M.; Fröehlich, P.E. Development and validation of dissolution test for ritonavir soft gelatin capsules based on in vivo data. Int. J. Pharm., 2007, 338(1-2), 119-124.
41. EMEA CPMP/EWP/QWP/1401/98, Note for guidance on the investigation of bioavailability and bioequivalence, Guideline on the investigation of bioequivalence 2008.
42. FDA Guidance for Industry, Dissolution testing of immediate release solid oral dosage forms 1997.
43. EMEA CPMP/QWP/604/96, Note for guidance on quality of modified release products 1999.